Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial

BACKGROUND: The inactivated COVID-19 whole-virus vaccine BBIBP-CorV has been extensively used worldwide. Heterologous boosting after primary vaccination can induce higher immune responses against SARS-CoV-2 than homologous boosting. The safety and immunogenicity after 28 days of a single Ad26.COV2.S...

Descripción completa

Detalles Bibliográficos
Autores principales: Muangnoicharoen, Sant, Wiangcharoen, Rakpong, Nanthapisal, Sira, Kamolratakul, Supitcha, Lawpoolsri, Saranath, Jongkaewwattana, Anan, Thitithanyanont, Arunee, Luvira, Viravarn, Chinwangso, Pailinrut, Thanthamnu, Narumon, Chantratita, Narisara, Lim, Jacqueline Kyungah, Anh Wartel, T., Excler, Jean-Louis, Ryser, Martin F., Leong, Chloe, Mak, Tippi K., Pitisuttithum, Punnee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267503/
https://www.ncbi.nlm.nih.gov/pubmed/37344265
http://dx.doi.org/10.1016/j.vaccine.2023.06.043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267503/
https://www.ncbi.nlm.nih.gov/pubmed/37344265
http://dx.doi.org/10.1016/j.vaccine.2023.06.043

Ejemplares similares